LncRNA AK023391 promotes tumorigenesis and invasion of gastric cancer through activation of the PI3K/Akt signaling pathway

Yanxia Huang¹, Jing Zhang¹*, Lidan Hou², Ge Wang¹, Hui Liu¹, Rui Zhang¹, Xiaoyu Chen¹ and Jinshui Zhu¹*

Abstract

Background: Patients with gastric cancer commonly have a poor prognosis, owing to its invasiveness and distant metastasis. Recent studies have confirmed the pivotal role of long non-coding RNAs (lncRNAs) in tumorigenesis and the progression of malignant tumors, including gastric cancer. However, little is known about the molecular mechanism by which lncRNA AK023391 contributes to gastric cancer.

Methods: A lncRNA microarray was used to identify the differentially expressed lncRNA AK023391 in gastric cancer and adjacent normal tissues. In addition, RNA fluorescence in situ hybridization (FISH) was used to investigate the association between AK023391 expression and the clinicopathological characteristics and prognosis of patients with gastric cancer. Subsequently, a series of in vitro assays and a xenograft tumor model were used to observe the functions of lncRNA AK023391 in gastric cancer cells. A cancer pathway microarray, bioinformatic analysis, western blotting, and immunochemistry were carried out to verify the regulation of AK023391 and its downstream PI3K/Akt signaling pathway.

Results: Expression of lncRNA AK023391 was significantly upregulated in gastric cancer samples and cell lines in comparison to adjacent normal tissues, and was positively correlated with poor survival in patients with gastric cancer. The multivariate Cox regression model revealed that AK023391 expression acted as an independent prognostic factor for survival in patients with gastric cancer. Knockdown of AK023391 inhibited cell growth and invasion both in vitro and in vivo, and induced apoptosis and cell cycle arrest in gastric cancer cells, whereas its overexpression reversed these effects. Mechanistically, PI3K/Akt signaling mediated the NF-κB, FOXO3a, and p53 pathways. Moreover, downstream transcription factors, such as c-myb, cyclinB1/G2, and BCL-6 might be involved in AK023391-induced tumorigenesis in gastric cancer.

Conclusions: The novel oncogenic lncRNA AK023391 in gastric cancer exerts its effects through activation of the PI3K/Akt signaling pathway, and may act as a potential biomarker for survival in patients with gastric cancer.

Keywords: lncRNA AK023391, Invasion, Gastric cancer, PI3K, Akt

* Correspondence: jing5522724@vip.163.com; zhujs1803@163.com
¹Department of Gastroenterology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, No. 600 Yishan Road, Shanghai 200233, China
Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Gastric cancer (GC) continues to be a major global health problem and is the third most frequent cause of cancer-related death, according to the Global cancer statistics 2012 findings [1]. Particularly in East Asia, it accounts for nearly more than half of the world’s GC burden [2]. The incidence of GC is relatively high, largely because of the popularity of endoscopic applications [3]. Although great progress has been made in the diagnosis and treatment of GC with the use of surgical techniques and/or adjuvant chemotherapy, the prognosis of affected patients remains relatively poor, as more than 80% of them are diagnosed at an advanced stage [4, 5]. Therefore, it is essential to discover novel potential biomarkers for the early diagnosis of GC.

The IncRNAs, a class of non-coding RNA transcripts longer than 200 nucleotides (nt) in length, with limited protein-coding capacity [7], have shown potential as biomarkers in the diagnosis and prognosis of cancer patients. This is because of their high specificity and sensitivity in serum, tissues, saliva, and urine [8]. According to the latest version of LNCipedia, more than 60,000 members of the IncRNA family have been cataloged [9, 10]. Evidence indicates that IncRNAs act either as negative or positive regulators of target gene expression, and their activity is directed either to target transcripts originating on other loci (trans-acting) or those originating from the same locus as the IncRNA itself (cis-acting) [11–13]. Accumulating data show that IncRNAs exert effects on a variety of biological processes, such as chromatin remodeling, cell differentiation, and carcinogenesis [14]. In addition, the dysregulation of IncRNAs is related to tumor proliferation, invasion, and metastasis of various types of cancer [15–18]. For example, MALAT1 predicts poor survival of cancer patients and accelerates cell invasion and metastasis by regulating miRNAs, key signaling pathways, and angiogenesis [19–21]. Recent studies show that the IncRNA small nucleolar RNA host gene 12 (SNHG12) facilitates tumorigenesis and metastasis by sponging miR-199a/b in hepatocellular carcinoma [22]. LncRNA SPRY4-IT1 encourages growth and metastasis of bladder cancer by sponging miR-101 [23], and LncRNAHOXA-AS2 induces cell proliferation and epithelial-mesenchymal transition (EMT) in gallbladder carcinoma [24]. Moreover, related studies about IncRNAs and GC demonstrate that multiple IncRNAs, such as HOXA11-AS, LINC00673, and XIST promote the progression of GC via regulation of β-catenin, L3D1, and miR-101 [23, 25, 26]; whereas, lin00261 inhibits its progression via Slug degradation [27], indicating that IncRNAs may act as potential biomarkers and therapeutic targets for GC.

In the present study, we identified the IncRNA AK023391 that was differentially expressed between GC and adjacent normal tissues, and evaluated the association between AK023391 expression and GC. We found that the expression of IncRNA AK023391 was increased in GC samples and cell lines in comparison to adjacent normal tissues, and was correlated with poor survival in patients with GC. Furthermore, functional in vitro and in vivo experiments, a cancer pathway array, western blotting, and immunohistochemistry (IHC) analyses showed that IncRNA AK023391 promoted tumorigenesis and the invasion of GC cells via activation of the PI3K/Akt signaling pathway.

Methods
Clinical data and cell culture
The human GC tissue microarray was purchased from Shanghai Outdo Biotech (Sample NO. HStm-Ade180Sur-07, Shanghai, P.R. China), and included 77 cases of patients with GC and pair-matched normal tissues. The protocols used in our study were approved by the Ethics Committee of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital. The GC specimens were classified according to the 2004 WHO criteria and the TNM staging system, and the clinicopathological characteristics of patients with GC from the tissue microarray are presented in Additional file 1: Table S1. Human GC cell lines (HGC-27, AGS, SGC-7901, BGC-823, and MGC-803) and gastric epithelial cells-1 (GES-1) were stored at the Digestive Disease Laboratory of Shanghai Sixth People’s Hospital. The cells were cultured in a humidified incubator with 5% CO2 at 37 °C in RPMI-1640 medium or Dulbecco’s modified Eagle’s medium (DMEM; KeyGen Biotech Co. Ltd) containing 10% fetal bovine serum (10% FBS).

LncRNA microarray analysis
Total RNA from GC (n = 5) and adjacent normal tissues (n = 5) was quantified using a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific), and RNA integrity was assessed using standard denaturing agarose gel electrophoresis. For microarray analysis, the Agilent array platform was employed. Sample preparation and microarray hybridization were performed according to the manufacturer’s standard protocols, with minor modifications. Briefly, mRNA was purified from total RNA after removal of rRNA (mRNA-ONLY™ Eukaryotic mRNA Isolation Kit, Epicentre). Each sample was then amplified and transcribed into fluorescent cRNA along the entire length of the transcripts without 3’ bias utilizing a random priming method. The labeled cRNAs were hybridized onto the Human LncRNA Array v2.0 (8 x 60 K, Arraystar). After having washed the slides, the arrays were scanned by the Agilent Scanner G2505C.

RNA fluorescence in situ hybridization (FISH)
Oligonucleotide primers (F:5′-AGTTGCGGTGCTCACCTGAGAGA-3′, R: 5′-ATTTGCTCATACTGCCC TG-3′) were used for IncRNA AK023391 FISH probe
amplification. First, the probe of AK023391 was labeled with digoxigenin (DIG) (Roche, 11,209,256,910) by in vitro transcription. The DIG-modified probe was then used to detect gene expression. The cell suspension was pipetted onto autoclaved glass slides, and the cells were washed with phosphate-buffered saline (PBS) and fixed in 4% paraformaldehyde. After dehydration with ethanol, hybridization was carried out at 37 °C overnight in a dark, moist chamber. After hybridization, slides were washed three times in 60 mL 50% formamide/2× SSC (sodium saline citrate) for 5 min, and were incubated with anti-DIG-HRP (Perkin Elmer, NEF832001EA) at 4 °C overnight. After being washed for 10 min at 25 °C, the slides were incubated with tyramide signal amplification (TSA) fluorescent signal reaction solution (Perkin Elmer, NEL701001KT, TSA Fluorescein system) for 30 min and sealed with tablets containing 4′,6-diamidino-2-phenylindole (DAPI). The images were acquired using a fluorescence microscope (Leica, SP8 laser confocal microscope).

Vectorivirus construction and cell transfection
Lentivirus-mediated IncRNA AK023391 siRNA (si-AK023391) or pEX-3-AK023391 (AK023391) was designed and produced by GeneChem Co. Ltd. (Shanghai, PR, China) and GenePharma Co. Ltd. (Shanghai, PR, China), respectively, and transfected into the GC cell lines with either high or low expression of AK023391. The following short hairpin RNA (shRNA) was used to target AK023391: AGGGCACACATATCTGTGT TA. The sequence of the negative control shRNA was TTCTCCGAACGTGTCAC GT. The primers specific for lncRNAs were designed and synthesized by Shanghai Sangon Biotech (Shanghai, P.R. China). The following procedures were performed: activation of enzymes at 95 °C for 5 min, 45 cycles of denaturation at 95 °C for 20 s, annealing at 60 °C for 30 s, and extension at 72 °C for 20 s. The relative expression levels of the IncRNAs were calculated using the 2-ΔΔCT method. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) or 18S rRNA was used as the internal control.

All qPCR reactions were performed in duplicate. The primers used in the present study are listed in Additional file 2: Table S2.

Cell viability assay
The GC cells (2 × 10^3/well) were seeded in 96-well plates at 37 °C with 5% CO_2. After transfection with si-AK023391 or AK023391 for 24, 48, 72, and 96 h, CCK-8 solution (10 μL) was added to each well, after which cells were incubated for 2 h. The optical densities at 492 nm were measured using a microplate reader (Molecular Devices Sunnyvale, CA, USA).

The 5-ethyl-2′-deoxyuridine incorporation assay
Based on the protocol outlined in the manual of the5-ethyl-2′-deoxyuridine (EdU) labeling/detection kit (RiboBio, Guangzhou, PR, China), 50 μM of EdU labeling medium was added to the cell culture that was incubated for 2 h at 37 °C with 5% CO_2. The cells were then fixed with 4% paraformaldehyde (pH 7.4) for 30 min and incubated with glycine for 5 min. After being washed with PBS, cells were stained with anti-EdU working solution at room temperature for 30 min. They were then washed with 0.5% Triton X-100 in PBS, and incubated with Hoechst33342 (5 μg/mL) at room temperature for 30 min. Cells were then observed using fluorescent microscopy. The percentage of EdU-positive cells was calculated from five random fields in three wells.

Wound-healing assay
Cells were seeded with a density of 1 × 10^6/well into 6-well plates and cultured to 90% confluence. Cell layers were scratched using a sterile 100 μL pipette tip to form wounded gaps. The plates were gently washed with PBS and cultured for 36 h. The wound gaps were photographed at the indicated time points.

Invasion and migration assay
The invasive potential of GC cells was measured using Matrigel (BD, Franklin Lakes, NJ, USA) and Transwell inserts (8.0 μm, Costar, Manassas, VA, USA) containing polycarbonate filters with 8-μm pores. The inserts were coated with 50 μL of 1 mg/mL Matrigel matrix, according to the manufacturer’s recommendations. Cells (8 × 10^5) in 200 μL of serum-free medium were plated in the upper chamber, whereas 700 μL of medium with 10% fetal bovine serum were added to the lower chamber. The migration assay was similar to the Matrigel invasion assay, except that the Transwell insert was not coated with Matrigel. After incubation for 24 h at 37 °C with 5% CO_2, cells that did not penetrate the membrane were removed with a cotton swab, whereas the migrated or invading cells were fixed with 0.1% crystal violet.
Colony formation assay
Briefly, GC cells \((2 \times 10^3)\) were plated into six-well plates and cultured for 15 days. Colonies were then fixed for 20 min with 10% formaldehyde and stained with 0.1% crystal violet for 10 min. The number of colonies containing \(\geq 50\) cells was counted under a microscope. Experiments were performed three times.

Apoptosis and cell cycle analysis
Apoptosis and cell cycle distribution were performed as previously described [28].

Pathway microarray analysis
To obtain unbiased findings on the LncRNAAK023391-associated signaling pathway, we assessed the differentially expressed genes, using the cancer pathway microarray (Agilent) in negative control (NC) and si-AK023391-transfected AGS cells. After transfection for 48 h, the differential expression profiles of AK023391-related pathway genes were analyzed, using the Agilent One-Color Microarray-Based Gene by KangChen (Shanghai, P.R. China). The Agilent Feature Extraction software (version 11.0.1.1) was used to analyze the acquired array images. Differentially expressed genes with statistical significance between the two groups were identified by volcano plot and fold change filtering. Hierarchical clustering was performed using R scripts, and Gene Ontology (GO) and pathway analyses were performed using the standard enrichment computation method.

Western blot analysis
Total protein lysates were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to a 0.22 \(\mu\)m polyvinylidene difluoride membrane (Millipore, Billerica, MA). They were then incubated with specific antibodies according to the manufacturer’s protocol. The GAPDH antibody was used as the control. The primary antibodies were as follows: FOXO3a (Abways, CY5079, Shanghai, P.R. China); p-FOXO3a (Abways, CY5562, Shanghai, P.R. China); PI3K (Abways, CY5355, Shanghai, P.R. China); p-PI3K (Abways, CY6427, Shanghai, P.R. China); GAPDH (Abways, AB0037, Shanghai, P.R. China).

![Fig. 1](image)

**Fig. 1** Expression of LncRNA AK023391 was upregulated in gastric cancer (GC). **a** LncRNA microarray analyses of five GC tissue samples and five corresponding adjacent normal tissues were performed. **b** LncRNA microarray identification of AK023391 and the most obvious changes in 20 upregulated LncRNAs and four downregulated LncRNAs. **c** qRT-PCR verification of the expression levels of 20 upregulated LncRNAs in GC tissues. **d** LncRNA expression profile and qRT-PCR analysis of the expression of AK023391 in GC tissues and adjacent normal tissues. T: tumor tissue; N: normal tissue.
Shanghai, P.R. China); AKT (Affinity Biosciences, AF6261, USA); p-AKT (Affinity Biosciences, AF016, USA); NF-κB (Affinity Biosciences, AF5006, USA); p-NF-κB (Affinity Biosciences, AF2006, USA); BCL-6 (Affinity Biosciences, DF2903, USA); c-Myb (Affinity Biosciences, AF6136, USA); p53 (Affinity Biosciences, AF0879, USA); cyclinG2 (Affinity Biosciences, DF2284, USA); cyclin B1 (Affinity Biosciences, AF6188, USA).

In vivo tumorigenesis assay
Male nude mice (6 weeks old) were purchased from Shanghai SIPPR-BK Laboratory Animal Co. Ltd. (Shanghai, P.R. China) and maintained in microisolator cages. All animals were used in accordance with institutional guidelines, and the current experiments were approved by the Use Committee for Animal Care. Each mouse was subcutaneously inoculated with $5 \times 10^6$ of SGC-7901 cells that had been resuspended in PBS with 50% Matrigel. The tumors observed in mice were measured every 3 days and the tumor volume was calculated according to the formula: length $\times$ width$^2$/2.

Immunohistochemistry (IHC) analysis
The GC tissues were immune-stained for Ki-67, p-NF-κB, p-Akt, p-PI3K, and p-FOXO3a, as previously described [28].

Statistical analysis
All quantitative data were expressed as mean ± SD. The Student’s $t$-test was used to compare quantitative variables. The Chi-squared test and Fisher’s exact test were used to compare categorical variables. The overall survival (OS) curve was analyzed by the Kaplan–Meier method and log-rank test. Univariate analysis and multivariate models were applied, using a Cox proportional hazards regression model. Receiver operating characteristic (ROC) curves were obtained using the Cutoff Finder online software (http://molpath.charite.de/cutoff/load.jsp). Statistical analysis and graph presentation were achieved, using the SPSS v.18.0 software (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 5 Software (GraphPad, San Diego, CA, USA). A value of $P < 0.05$ was considered statistically significant.

Results
Upregulation of lncRNA AK023391 in GC tissues
To identify the unique genes involved in GC progression, the lncRNA microarray analysis was performed using total RNA isolated from five GC samples and five adjacent normal tissues. Based on a fold change > 2.0 and $P$-value < 0.05, about 1894 upregulated lncRNAs and 167 downregulated lncRNAs were identified, in comparison to the adjacent normal tissues (Fig. 1a). Furthermore, based on a fold change > 2.0 and $P$-value < 0.02, the most obvious changes

Huang et al. Journal of Experimental & Clinical Cancer Research (2017) 36:194 Page 5 of 14

![Fig. 2](image-url)

**Fig. 2** Expression of lncRNA AK023391 was associated with poor survival in patients with gastric cancer (GC). a Fluorescence in situ hybridization (FISH) analysis of the expression and cellular localization of lncRNA AK023391 in 77 patients with GC and pair-matched normal tissues. b qRT-PCR analysis of AK023391 expression in different GC cell lines and GES-1. c Receiver operating characteristic (ROC) curve analysis of the cutoff value, sensitivity, specificity and area under the curve (AUC) of AK023391 in patients with GC. d Kaplan–Meier analysis of the correlation of AK023391 expression with survival in patients with GC, as well as early stage patients. *$P < 0.05$, **$P < 0.01$
in 20 upregulated lncRNAs and four downregulated lncRNAs were screened for cluster analysis. Among those screened, uc003yqp.1 (also referred to as lncRNA AK023391) had the most pronounced difference between GC and adjacent normal tissue, and was thus selected for further study (Fig. 1b). The expression levels of the 24 lncRNAs were further validated in GC tissues by qRT-PCR analysis. Among those lncRNAs, AK023391 showed the highest expression level (Fig. 1c). In addition, the increased expression of lncRNA AK023391 in GC tissues was verified by microarray expression profiling and qRT-PCR analysis (Fig. 1d).

Expression of lncRNA AK023391 is associated with poor survival in patients with GC

To confirm the aforementioned results, the expression of lncRNA AK023391 was further determined in another 77 cases of patients with GC and pair-matched normal tissues by FISH analysis. The results demonstrated that AK023391 expression was upregulated in GC and was mainly localized in the cytoplasm of the tissue cells (Fig. 2a). The expression of AK023391 was examined in different GC cell lines by qRT-PCR analysis. The results showed significantly increased expression of AK023391 in GC cell lines in comparison to GES-1, especially in SGC-7901, AGS, and HGC-27 cell lines (Fig. 2b).

We investigated whether the expression of AK023391 was associated with clinical and pathological features, and the prognosis of patients with GC. Thus, as shown in Fig. 2c, based on the cutoff value of AK023391 (that was calculated by its expression level, OS time, and survival status in GC tissues), we classified the patients with GC into two groups: AK023391 high expression and AK023391 low expression. Further analysis showed that the AK023391 high expression group showed no correlation with age, gender, tumor size, pathological stage, TNM stage, or lymphatic invasion (each \( P > 0.05 \), Additional file 3: Table S3). Kaplan–Meier and Cox regression analyses were used to assess the association between AK023391 expression and OS of patients with GC. The results indicated that patients in the AK023391 high expression group showed a shorter OS time in comparison to those in the AK023391 low expression group, as well as those with early stage GC (stage I + II).
(Fig. 2d), as opposed to those patients with late stage GC (stage III + IV) (Additional file 4: Figure S1). Multivariate analysis revealed that AK023391 expression, as well as the N stage were independent prognostic factors for OS in patients with GC (Additional file 5: Table S4).

Knockdown of AK023391 inhibits the proliferation, colony formation, and DNA synthesis of GC cells

To determine whether lncRNA AK023391 affects GC cell proliferation, we transfected HGC-27, AGS, and SGC-7901 cell lines with si-AK023391 or NC. Cell proliferation, colony formation capacity, and DNA synthesis were determined by CCK-8, colony formation, and EdU assays, respectively. Knockdown efficiency of AK023391 was confirmed by qRT-PCR analysis. This analysis indicated that AK023391 expression in si-AK023391-transfected HGC-27, AGS, and SGC-7901 cells was substantially reduced by more than 50% (P < 0.01, Fig. 3a). Thus, the interference ability of si-AK023391 was both effective and specific. CCK-8 and cell colony formation assays showed that the proliferation activity and colony formation ability of HGC-27, AGS, and SGC-7901 cells showed significant decline after knockdown of AK023391 (Fig. 3b, c). Subsequently, the EdU assay was performed to assess the effect of si-AK023391 on DNA synthesis of HGC-27, AGS, and SGC-7901 cells. The results indicated that the DNA synthesis capability of these cells demonstrate a trend toward marked reduction by silencing AK023391 (Fig. 4).

Knockdown of AK023391 suppresses the migration and invasion of GC cells

The wound-healing and Transwell assays were further conducted to assess whether lncRNA AK023391 affects the migration and invasion abilities of HGC-27, AGS, and SGC-7901 cells. The migration abilities of HGC-27, AGS, and SGC-7901 cells in the si-AK023391-transfected group showed significant decline after being wounded for 36 h (Fig. 5a) or being passed through the polycarbonate membrane for 24 h (Fig. 5b). Furthermore, the Transwell chamber (with Matrigel) assay demonstrated that the invasive potential of HGC-27, AGS, and SGC-7901 cells was also remarkably weakened in the si-AK023391-transfected group after being passed through the polycarbonate membrane coated with Matrigel for 24 h (Fig. 5c). These findings suggest that knockdown of AK023391reduced the migration and invasion abilities of GC cells.

Knockdown of AK023391 induces apoptosis and cell cycle arrest

Flow cytometry analysis was performed to evaluate the effects of lncRNA AK023391 on apoptosis and cell cycle distribution of HGC-27, AGS, and SGC-7901 cells. The results indicated that the proportion of these cells in apoptosis was significantly increased after the silencing of AK023391 (Fig. 6a). Cell cycle distribution showed that the proportion of HGC 27, AGS, and SGC-7901 cells was increased in the G0/G1 phase, but decreased in...
the S phase in the si-AK023391-transfected group (Fig. 6b). These results reveal that knockdown of AK023391 induced GC apoptosis and cell cycle arrest.

**Overexpression of AK023391 promotes the proliferation, colony formation, and invasion of GC cells**

Having verified the inhibitory effects of AK023391 knockdown in GC cells, we further constructed the pEX-3-AK023391 overexpression vector. This vector was transfected into the MGC-803 and BGC-823 cell lines with AK023391 low expression to evaluate the effects of AK023391 overexpression. First, the transfection efficiency of AK023391 overexpression was estimated by qRT-PCR analysis in MGC-803 and BGC-823 cell lines (Fig. 7a). The cell proliferation activities, colony formation capacity, and invasive potential were then assessed by CCK-8, colony formation, and Transwell assays. The results of these assays showed that the proliferation activities (Fig. 7b) and colony formation (Fig. 7c, d) of MGC-803 and BGC-823 cells were significantly increased after overexpression of AK023391. In addition, the cell invasive potential of MGC-803 and BGC-823 cells showed a trend toward a substantial increase following overexpression of AK023391 (Fig. 7e, f).
LncRNA AK023391 is involved in the regulation of the PI3K/Akt signaling pathway

To identify key downstream signaling pathways that are regulated by lncRNA AK023391 and involved in GC progression, cancer pathway microarray analysis was conducted, using total RNA isolated from si-AK023391 and NC-transfected AGS cells. Based on a fold change > 2.0 and a P-value < 0.05, about 113 upregulated genes and 315 downregulated genes were identified after AK023391 knockdown, in comparison to the NC (Fig. 8a). Enrichment of the downregulated coding genes that might be implicated in promoting carcinogenesis was analyzed, using the database for annotation, visualization, and integrated discovery (DAVID, http://david.abcc.ncifcrf.gov/). The Kyoto Encyclopedia of Genes and Genomes (KEGG) database (http://www.genome.jp/kegg/) was applied to analyze the possible biological pathways, in which there was significant enrichment of the genes downregulated by AK023391 knockdown, in comparison to the NC (Fig. 8a). Enrichment of the downregulated coding genes that might be implicated in promoting carcinogenesis was analyzed, using the database for annotation, visualization, and integrated discovery (DAVID, http://david.abcc.ncifcrf.gov/). The Kyoto Encyclopedia of Genes and Genomes (KEGG) database (http://www.genome.jp/kegg/) was applied to analyze the possible biological pathways, in which there was significant enrichment of the genes downregulated by AK023391 knockdown. The KEGG analysis showed that the downregulated genes might be related to different signaling pathways, among which 10 of the most important enriched pathways were available (Fig. 8b). We also assessed the ability of the FOXO and PI3K/Akt signaling pathways to regulate AK023391. Interestingly, the gene ratio and enrichment score analysis showed that PI3K/Akt and FOXO signaling pathways, respectively had the most obvious enrichment among the pathways altered by AK023391 knockdown (Fig. 8c).

Furthermore, the altered coding genes closely associated with these two enriched pathways that were affected by si-AK023391 were screened for cluster analysis (Fig. 8d). The results of this analysis revealed that some of the key genes associated with important pathways, such as AKT, p53, and NF-κB, and transcript factors, such as c-myb, cyclinB1/G2, and BCL-6 showed significant differential expressions between the si-AK023391 and NC groups and were involved in cancer progression. The results of the GO analysis showed that these genes, as downstream regulation elements, were implicated in the regulation of PI3K/Akt and FOXO signaling pathways (Additional file 6: Figure S2). Western blotting analysis further confirmed the changes observed in the expression of these genes in the PI3K/Akt and FOXO pathways of the si-AK023391 or NC-transfected HGC-27, AGS, and SGC-7901 cells. These findings indicate that knockdown of AK023391 downregulated the expression of phosphorylated PI3K (p-PI3K), p-Akt, p-NF-κB, c-myb, cyclinB1/G2, and BCL-6, but upregulated the expression of p-FOXO3a and p53 in HGC-27, AGS, and SGC-7901 cells (Fig. 8e, f). No significant differences in expression were evident for PI3K, Akt, NF-κB, and FOXO3a between the si-AK023391 and NC groups.

Knockdown of lncRNA AK023391 inhibits tumor growth in vivo

To further explore whether lncRNA AK023391 influences tumor growth in vivo, we constructed si-AK023391 or NC
stably transfected SGC-7901 cells that were then subcutaneous injected into the flank of nude mice. After 30 days, we found that the tumor volumes of si-AK023391-transfected SGC-7901 cells were significantly less than those of NC-transfected SGC-7901 cells (Fig. 9a). The xenograft tumor growth curve demonstrated that the tumors of the si-AK023391 transfected group grew much more slowly in a time dependent manner (Fig. 9b). Statistical analysis of tumor weight and volume on the final day of the experimental period, showed them both to be much lower in the si-AK023391-transfected group than in the NC-transfected group (Fig. 9c). In addition, IHC analysis was conducted to determine whether AK023391 affects the expression changes of Ki-67, p-FOXO3a, p-PI3K, p-Akt, and p-NF-κB in xenograft tumor tissues. The results showed that knockdown of AK023391 significantly downregulated the expression of Ki-67, p-PI3K, p-Akt, and p-NF-κB, but upregulated p-FOXO3a expression (Fig. 9d and Additional file 7: Figure S3). These results indicate that knockdown of AK023391 suppressed GC growth via inactivation of the PI3K/Akt pathway.

**Discussion**

Recent studies indicate that lncRNAs play critical roles in tumorigenesis and metastasis of a variety of cancers [29–33]. They are significantly altered in GC tissues as evidenced by lncRNA expression profile analysis, and participate in multiple tumor biological processes. For example, LINC00673 is upregulated in GC, and is associated with a poor prognosis in affected patients [25]; and lnc00152 is involved in cell cycle arrest, apoptosis, EMT, migration, and invasion in GC [34]. Moreover,
LncRNA AK023391 was involved in the regulation of the PI3K/Akt signaling pathway. a Pathway expression profile analysis of differentially expressed coding genes caused by si-AK23391 in AGS cells. b KEGG enrichment analysis of the 10 most important enriched pathways involved in the regulation of AK23391 in gastric cancer (GC) cells. c Gene ratio and enrichment score analysis revealed that PI3K/Akt and FOXO signaling pathways, respectively, had the most obvious enrichment among the altered pathways induced by AK023391 knockdown. d Cluster analysis of the differentially expressed genes involved in the PI3K/Akt and FOXO signaling pathways, induced by AK023391 knockdown. e-f Western blotting validation of the effects of AK023391 knockdown on the expression of PI3K/Akt, NF-κB, p53, and FOXO3a pathways, and their downstream transcription factors c-myb, cyclinB1/G2, and BCL-6 in HGC 27, AGS, and SGC-7901 cells.

Fig. 9 Knockdown of AK023391 inhibited tumor growth in vivo. a Schematic representation of the SGC-7901 xenograft tumor size after 30 d of tumor growth in the si-AK023391 and negative control (NC) groups. b Tumor growth curve of the SGC-7901 xenograft tumor growth tendency in the si-AK023391 and NC groups. c Statistical comparison of the differences in tumor weight and volume between the si-AK023391 and NC groups. d IHC analysis of the expression levels of Ki-67, p-FOXO3a, p-PI3K, p-Akt, and p-NF-κB in xenograft tumor tissues treated with si-AK023391 and in the NC group (original magnification, ×200). e LncRNA AK023391 promoted GC tumorigenesis and invasion through activation of the PI3K/Akt pathway that further activated NF-κB, inactivated FOXO3a, upregulated c-myb, cyclinB1/G2, and BCL-6, and downregulated p53 expression.
lncRNA MALAT1 promotes GC tumorigenicity and metastasis by regulating angiogenesis [20], indicating some of the important roles of lncRNAs in GC.

In the present study, we identified for the first time, to our knowledge, the novel lncRNA AK023391 through lncRNA expression profiling. Furthermore, we verified that it is upregulated in GC tissues and cell lines, suggesting a critical role of AK023391 in GC. Although FISH analysis with a tissue microarray indicated no association between AK023391 expression and the clinicopathological characteristics of 77 patients with GC, Kaplan–Meier analysis showed that high expression of AK023391 was positively correlated with poor survival in patients with GC. In addition, multivariate analysis revealed AK023391 expression as an independent prognostic factor for the OS of patients with GC.

Subsequently, functional in vitro and in vivo experiments were conducted to investigate the effects of AK023391 on GC cell growth and invasion. Our results showed that knockdown of AK023391 suppressed GC cell proliferation, colony formation, migration, invasion, and xenograft tumor growth, and induced apoptosis and cell cycle arrest, whereas overexpression of AK023391 promoted cell proliferation, colony formation, and invasion. Thus, our observations combined with clinical data strongly suggest that AK023391 might be an oncogenic lncRNA in GC.

The PI3K/Akt/FOXO and NF–κB signaling pathways are constitutively activated in various cancers, including breast cancer, prostate cancer, GC, and pancreatic cancer [35–39], and result in cancer initiation and progression. Interestingly, a variety of lncRNAs regulate the activity of the PI3K/Akt signaling pathway in cancer. For example, Linc00152 promotes GC growth through activation of the epidermal growth factor receptor (EGFR)-dependent PI3K/Akt pathway [40]; lncRNA BC087858 induces lung cancer invasion and drug resistance to EGFR through activation of the PI3K/Akt pathway [41]; and MALAT1 accelerates cholangiocarcinoma progression through activation of the PI3K/Akt pathway [42]. Our current study revealed that lncRNA AK023391 was localized mainly in the cytoplasm of GC tissue cells, suggesting that cytoplasmic AK023391 acted as a key mediator of signal transduction in GC. The cancer pathway array and western blotting analysis confirmed that the PI3K/Akt pathway and its downstream FOXO, NF-κB, and p53 pathways were involved in the regulation of AK023391 in GC tumorigenesis. Western blotting analysis showed that the expression levels of phosphorylated PI3K and Akt in the LncRNA si-AK023391 group were significantly reduced, but not total PI3K or Akt, indicating that the PI3K/Akt pathway might be involved in AK023391-induced tumorigenesis and invasion of GC through regulation of the phosphorylation level of PI3K/Akt pathway. The PI3K family can recruit and activate a number of proteins, including Akt, by generating second messenger lipid phosphatidylinositol (3,4,5)-triphosphate (PIP3). Then AKT encodes a serine/threonine kinase, and becomes activated through phosphorylation. This activation can further mediate the activation of target genes, and act a role in regulation of cell proliferation, survival, angiogenesis, invasion, and metastasis [43].

Furthermore, the cancer pathway array, KEGG, and western blotting analyses were performed to identify the downstream transcription factors of the PI3K/Akt pathway, such as p53, c-myb, cyclinB1/G2, and BCL-6 that mediate the activity of AK023391 in promoting GC tumorigenesis. These transcription factors are known to be essential for tumor proliferation, apoptosis, and invasion [44–46]. They thus mediate the PI3K/Akt pathway to regulate apoptosis, proliferation, and invasion in GC and acute promyelocytic leukemia [47, 48]. Therefore, we speculated that lncRNA AK023391 promotes GC tumorigenesis and invasion through activation of the PI3K/Akt pathway. This activation might further activate NF-κB, inactivate FOXO3a, upregulate c-myb, cyclinB1/G2, and BCL-6 expression, and downregulate p53 expression, thereby promoting GC progression (Fig. 9e).

Conclusions

In summary, our findings demonstrate that lncRNA AK023391 promotes tumorigenesis and invasion of GC cells through activation of the PI3K/Akt pathway, and has the potential to act as a promising biomarker for survival in GC.

Additional files

Additional file 1: Table S1. Clinicopathological data of GC patients. (DOCX 25 kb)

Additional file 2: Table S2. Prime sequences of lncRNAs. (DOCX 24 kb)

Additional file 3: Table S3. Correlation of lncRNA AK023391 expression with clinicopathologic features of GC patients. (DOCX 25 kb)

Additional file 4: Kaplan–Meier analysis of the correlation of AK023391 expression with survival in late stage patients. (TIFF 172 kb)

Additional file 5: Table S4. Univariate and multivariate Cox regression analysis of overall survival duration. (DOCX 22 kb)

Additional file 6: GO analysis showed that c-myb, cyclinB1/G2, and BCL-6 as downstream regulation elements, were implicated in the regulation of PI3K/Akt and FOXO signaling pathways. (TIFF 800 kb)

Additional file 7: Quantitative analysis of IHC showed that knockdown of AK023391 significantly downregulated the expression of Ki-67, p-PI3K, p-Akt, and p-NF-κB, but upregulated p-FOXO3a expression in tumor tissues. (TIFF 248 kb)

Abbreviations

Akt: Protein kinase B; AUC: Area under the curve; Bcl-6: B-cell lymphoma 6; CCK-8: Cell counting kit 8; DAPI: 4′,6-diamidino-2-phenylindole; DAVID: Database for annotation, visualization and integrated discovery; DIG: Digoxigenin; DMEM: Dulbecco’s modified Eagle’s medium; Edu: 5-ethynyl-2-deoxyuridine; EGFR: Epidermal growth factor receptor; EMT: Epithelial-
mesenchymal transition; FBS: Fetal bovine serum; FSH: Fluorescence in situ hybridization; FOXO3a: Forkhead box O3A; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; GC: Gastric cancer; GO: Gene ontology; IHC: Immunohistochemistry; KEGG: Kyoto encyclopedia of genes and genomes; lncRNA: Long non-coding RNAs; MALAT1: Metastasis associated lung adenocarcinoma transcript 1; NC: Negative control; NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells; OS: Overall survival; PBS: Phosphate-buffered saline; PCR: Polymerase chain reaction; PKS: Phosphokinase 3-kinase; ROC: Receiver operating characteristic; TSA: Tyramide signal amplification

Funding
Our work was supported by grants from the National Natural Science Foundation of China (No. 81573477), Hong Kong Scholars Program (No. X2015033), Shanghai Science and Technology Commission Western Medicine Guide project (No. 17411965500) and Shanghai Jiao Tong University School of Medicine doctoral innovation fund (No. BX201737).

 Availability of data and materials
All data in our study are available upon request.

Authors’ contributions
YXH and JZ contributed equally to this article. JSZ and JZ designed the experiment. YXH and DH performed the experiments and YXH and JZ wrote the manuscript. GW and HL supported the experiments. JZ, RZ and YXH conducted the data analysis. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The present study was approved by the Hospital’s Protection of Human Subjects Committee.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Gastroenterology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, No. 600 Yishan Road, Shanghai 200233, China.
2Department of Gastroenterology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Received: 14 November 2017 Accepted: 14 December 2017
Published online: 28 December 2017

References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):8–10.
2. Chen W, Zheng R, Baade PD, Zeng H, Bray F, Jemal A, Yi, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–39.
3. Yu H, Wu S, Wu T, Mai L, Zhao L, Wang X, et al. LncRNA SPRY4-IT1 sponges miR-101-3p to promote proliferation and metastasis of gastric cancer. Cancer Lett. 2017;395:311–19.
4. Chen D, Huang J, Qiu MZ, Wang DS, et al. Long non-coding RNA HOXA-AS2 promotes proliferation and induces epithelial-mesenchymal transition in gallbladder carcinoma. Oncotarget. 2017;8(17):28297–301.
5. Quan Z-W. Long non-coding RNA Malat1 promotes gallbladder cancer development by acting as a molecular sponge to regulate miR-206. Oncotarget. 2016;7(25):37857–67.
6. Li Y, Wu Z, Yuan J, Sun L, Lin L, Huang N, Bin J, Liao Y, Liao W. Long non-coding RNA MALAT1 promotes gastric cancer tumorigenicity and metastasis by down-regulating the expression of ZEB2. Mol Cancer. 2018;17(1):17.
7. Lu Z, Li Y, Wang J, Che Y, Sun S, Huang J, Chen Z, He J. Long non-coding RNA RNKLA inhibits migration and invasion of non-small cell lung cancer via NF-κB/Smad pathway. J Exp Clin Cancer Res. 2017;36(1):54.
8. Chen QN, Chen X, Chen ZY, Nie FQ, Wei CC, Ma HW, Wan L, Yan S, Ren SN, Wang ZX. Long intergenic non-coding RNA 00152 promotes lung adenocarcinoma proliferation via interacting with EZH2 and repressing ILC2 expression. Mol Cancer. 2017;16(1):17.
9. Chen QN, Chen X, Chen ZY, Nie FQ, Wei CC, Ma HW, Wan L, Yan S, Ren SN, Wang ZX. Long intergenic non-coding RNA 00152 promotes lung adenocarcinoma proliferation via interacting with EZH2 and repressing ILC2 expression. Mol Cancer. 2017;16(1):17.
10. Volders PJ, Helsens K, Wang X, Menten B, Martens L, Gevaert K, Vandesompele J, Westdagh P. LNCipedia: a database for annotated human lncRNA transcript sequences and structures. Nucleic Acids Res. 2013;41(Database issue):D406–11.
11. Volders PJ, Verheggen K, Menschaert G, Vandesompele K, Martens L, Vandesompele J, Westdagh P. An update on LNCipedia: a database for annotated human lncRNA sequences. Nucleic Acids Res. 2015;43(Database issue):D174–80.
12. Huang M, Hou J, Wang Y, Xie M, Wei C, Nie F, Wang Z, Sun M. Long non-coding RNA XIST regulates gastric cancer progression by acting as a molecular sponge of miR-101 to modulate EZH2 expression. J Exp Clin Cancer Res. 2016;35(1):142.
39. Amin H, Wani NA, Farooq S, Nayak D, Chakraborty S, Shankar S, Rasool RU, Hao NB, Tang B, Wang GZ, Xie R, CJ H, Wang SM, YY W, Liu E, Xie X, Huang.

40. Zhou J, Zhi X, Wang L, Wang W, Li Z, Tang J, Wang J, Zhang Q, Xu Z. The long non-coding RNA XIST conjugate of EPA with β-Koul S, Goswami A, Rai R. Inhibition of invasion in pancreatic cancer cells by k expression via the PI3K/Akt/NF-

41. Pan H, Jiang T, Cheng N, Wang Q, Ren S, Li X, Zhao C, Zhang L, Cai W, Zhou C. Long non-coding RNA BC087898 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer. Oncotarget. 2016;7(31):49948–49.

42. Wang C, Mao ZP, Wang L, GH W, Zhang FH, Wang DY, Shi JL. Long non-coding RNA MALAT1 promotes cholangiocarcinoma cell proliferation and invasion by activating PI3K/Akt pathway. Neoplasma. 2017;64(5):725–31.

43. Bartholomeusz C, Gonzalez-Angulo AM. Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:121–30.

44. Li Y, Jin K, van Pelt GW, van Dam H, Yu X, Mesker WE, Ten Dijke P, Zhou F, Zhang L. C-Myc enhances breast cancer invasion and metastasis through the Wnt/beta-catenin/Axin2 pathway. Cancer Res. 2016;76(11):3364–75.

45. Liu J, Cui ZS, Luo Y, Jiang L, Man XH, Zhang X. Effect of cyclin G2 on proliferative ability of SGC-7901 cell. World J Gastroenterol. 2004;10(9):357–60.

46. Shi Q, Wang W, Jia Z, Chen P, Ma K, Zhou C. ISL1, a novel regulator of CCNB1, CCNB2 and c-MYC genes, promotes gastric cancer cell proliferation and tumor growth. Oncotarget. 2016;7(24):36489–500.

47. Li Y, Qu X, Qu J, Zhang Y, Liu J, Teng Y, Hu X, Hou K, Liu Y. Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation. Cancer Lett. 2009;284(2):208–15.

48. Wu X, Chen Y, Li G, Xia L, Gu R, Wen X, Ming X, Chen H. Her3 is associated with poor survival of gastric adenocarcinoma: Her3 promotes proliferation, survival and migration of human gastric cancer mediated by PI3K/AKT signaling pathway. Med Oncol. 2014;31(4):1003.